Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process
Mandate

Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process

August 17, 2018

In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million.

Following the transaction, Industrifonden holds approximately 23.67% of the shares in Oncopeptides.
 
Vinge’s team consisted of Dain Hård Nevonen, Rikard Lindahl and Sofie Bjärtun.

Related

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

 Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025

Vinge is advising on the establishment of Ballista Capital

 Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025